Institutional & Family Asset Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $2.03K | Hold |
400
| – | – | ﹤0.01% | 576 |
|
|
2024
Q1 | $3.39K | Hold |
400
| – | – | ﹤0.01% | 532 |
|
|
2023
Q4 | $1.64K | Hold |
400
| – | – | ﹤0.01% | 572 |
|
|
2023
Q3 | $1.2K | Buy |
400
+200
| +100% | +$601 | ﹤0.01% | 598 |
|
|
2023
Q2 | $6.18K | Hold |
200
| – | – | ﹤0.01% | 449 |
|
|
2023
Q1 | $9.9K | Hold |
200
| – | – | ﹤0.01% | 380 |
|
|
2022
Q4 | $4.92K | Hold |
200
| – | – | ﹤0.01% | 475 |
|
|
2022
Q3 | $13K | Hold |
200
| – | – | ﹤0.01% | 349 |
|
|
2022
Q2 | $8K | Hold |
200
| – | – | ﹤0.01% | 411 |
|
|
2022
Q1 | $10K | Hold |
200
| – | – | ﹤0.01% | 433 |
|
|
2021
Q4 | $12K | Hold |
200
| – | – | ﹤0.01% | 415 |
|
|
2021
Q3 | $10K | Hold |
200
| – | – | ﹤0.01% | 538 |
|
|
2021
Q2 | $11K | Buy |
200
+67
| +50% | +$3.69K | ﹤0.01% | 568 |
|
|
2021
Q1 | $8K | Hold |
133
| – | – | ﹤0.01% | 596 |
|
|
2020
Q4 | $9K | Hold |
133
| – | – | ﹤0.01% | 550 |
|
|
2020
Q3 | $34K | Hold |
133
| – | – | 0.01% | 330 |
|
|
2020
Q2 | $22K | Hold |
133
| – | – | ﹤0.01% | 388 |
|
|
2020
Q1 | $9K | Hold |
133
| – | – | ﹤0.01% | 459 |
|
|
2019
Q4 | $9K | Hold |
133
| – | – | ﹤0.01% | 512 |
|
|
2019
Q3 | $8K | Hold |
133
| – | – | ﹤0.01% | 499 |
|
|
2019
Q2 | $8K | Hold |
133
| – | – | ﹤0.01% | 521 |
|
|
2019
Q1 | $9K | Hold |
133
| – | – | ﹤0.01% | 510 |
|
|
2018
Q4 | $7K | Hold |
133
| – | – | ﹤0.01% | 523 |
|
|
2018
Q3 | $8K | Hold |
133
| – | – | ﹤0.01% | 548 |
|
|
2018
Q2 | $8K | Hold |
133
| – | – | ﹤0.01% | 553 |
|
|
2018
Q1 | $6K | Buy |
+133
| New | +$6K | ﹤0.01% | 570 |
|